玻璃体腔注射雷珠单抗注射液治疗眼底病的效果

Abstract
Figure/Table
References (15)
Related Citation (8)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of intravitreal injection of Ranibizumab on treatment of ocular fundus disease. Methods A total of 100 patients with ocular fundus disease treated in our hospital from January 2018 to October 2019 were selected as the research subjects and divided into the control group and the observation group by random number table method, with 50 cases in each group. Patients in the control group were treated with conventional drugs, while patients in the observation group were treated with intravitreal injection of Ranibizumab on the basis of conventional drugs. The total effective rate, symptom disappearance time, clinical symptom improvement and hemodynamic indicators were compared between the two groups. Results The total effective rate in the observation group(92.00%) was higher than that of the control group (72.00%), and the difference was statistically significant (P＜0.05).The retinal edema disappearance time, normal retinal thickness recovery time, retinal hemorrhage disappearance time and neovascularity disappearance time of the observation group were shorter than those of the control group, and the differences were statistically significant (P＜0.05). After treatment, the eyesight of the observation group was higher than that of the control group, the intraocular pressure and retinal thickness of the observation group were lower than those of the control group, and the differences were statistically significant (P＜0.05). After treatment, the whole blood viscosity, plasma viscosity, hematocrit and red blood cell aggregation index of the observation group were lower than those of the control group, and the differences were statistically significant (P ＜0.05). Conclusion Intravitreal injection of Ranibizumab has a significant effect on treatment of ocular fundus disease and is worthy of clinical application and promotion.

Key words： Vitreous cavity Ranibizumab Ocular fundus disease

Received: 03 April 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/146

[1]	张喜梅，徐晓莉，李洁，等.息肉样脉络膜血管病变患眼玻璃体腔注射雷珠单抗治疗前后眼底自身荧光影像特征观察[J].中华眼底病杂志，2017，33（6）：587-592.
[2]	贾媛媛，喻晓兵，叶红，等.玻璃体腔注射雷珠单抗治疗缺血型和非缺血型视网膜中央静脉阻塞继发黄斑水肿一年疗效对比观察[J].中华眼底病杂志，2018，34（5）：443-447.
[3]	张妍春，任秀瑜，伍玉洁.玻璃体腔注射雷珠单抗治疗脉络膜骨瘤并发脉络膜新生血管1 例[J].中国中医眼科杂志，2019，29（6）：482-484.
[4]	付浴东，孟旭霞，王萍，等.不同光相干断层扫描分型糖尿病黄斑水肿玻璃体腔注射雷珠单抗的疗效差异及椭圆体带完整性与视力相关性观察[J].中华眼底病杂志，2017，33（2）：129-133.
[5]	王相宁，李淑婷，杜新华，等.不同光相干断层扫描分型糖尿病黄斑水肿患眼玻璃体腔注射雷珠单抗与激光光凝治疗后视力观察[J].中华眼底病杂志，2017，33（2）：134-138.
[6]	连海燕，宋艳萍，丁琴.玻璃体腔注射雷珠单抗治疗渗出型老年性黄斑变性患眼随访2年终末视力与基线特征相关性观察[J].中华眼底病杂志，2017，33（1）：40-43.
[7]	傅维娜，陈梅珠，王云鹏.手术前玻璃体腔注射雷珠单抗对增生型糖尿病视网膜病变患眼玻璃体切割手术操作时间及手术后视力的影响[J].中华眼底病杂志，2016，32（1）：26-30.
[8]	梁燕华，宋艳萍，丁琴，等.单纯光动力疗法与玻璃体腔注射雷珠单抗以及两者联合治疗息肉样脉络膜血管病变疗效比较[J].中华眼底病杂志，2016，32（1）：31-35.
[9]	张霜，张杰，徐鑫彦，等.组织型纤溶酶原激活剂、雷珠单抗联合C3F8 治疗息肉样脉络膜血管病变并发早期黄斑下出血的疗效观察[J].中华眼底病杂志，2018，34（5）：448-452.
[10]	杨琳，金学民，周朋义.贝伐单抗和雷珠单抗玻璃体腔注射治疗病理性近视脉络膜新生血管的疗效对比观察[J].中华眼底病杂志，2017，33（2）：139-143.
[11]	曹素平.玻璃体腔注射雷珠单抗治疗眼底病的临床疗效观察与应用价值分析[J].中国农村卫生，2019，11（21）：40-41.
[12]	吴志鹏，李佳，綦占娇，等.玻璃体腔注射雷珠单抗注射液治疗眼底病的效果[J].中国现代药物应用，2019，13（5）：6-8.
[13]	张阳沫，倪宁华.雷珠单抗治疗早产儿视网膜病变的研究进展[J].昆明理工大学学报（自然科学版），2019，44（2）：75-80.
[14]	宋爽，张鹏，谷潇雅，等.玻璃体腔注射雷珠单抗后患眼短期眼压升高的影响因素分析[J].中华眼底病杂志，2018，34（5）：432-435.
[15]	康皞，王彬.玻璃体腔注射雷珠单抗对眼底病患者血流动力学的影响[J].中国医学工程，2017，25（9）：29-31.